HLA-C and melanoma: Ghorani et al. (4) and Retch et al. (5) independently examined mutational and clinical outcome data from several thousand patients and, remarkably, concluded that presence or absence of high-affinity MHC-binding neoepitopes in tumors had no correlation with overall survival, progression-free survival, or T cell infiltration in tumors, while the presence of low affinity was powerfully correlated with all clinical endpoints in melanoma and lung cancers (4) and in 27 different tumor types (5).